On March 28th, the journal "Cell" published an online research paper titled "Flexible Scaffold-based Cheminformatics Approach for Polypharmacological Drug Design".

Immunome, Inc. plans to reveal early data on IM-3050, their lead drug featuring lutetium-177, targeting the fibroblast activation protein.

X4 Pharmaceuticals announced preliminary results from its Phase 2 trial evaluating the safety and efficacy of once-daily oral mavorixafor with or without injected G-CSF in patients with idiopathic, cyclic, or congenital neutropenia.

Werewolf Therapeutics Reveals Early Stage Study Outcomes Highlighting the Cancer-Fighting Capabilities of Immune-Stimulating Drugs WTX-518 and WTX-712.

Deucrictibant is a new, potent oral small-molecule bradykinin B2 receptor antagonist, originally developed by the Pharvaris team.

Edgewood Oncology reveals encouraging outcomes from a research-driven trial for BTX-A51 in early tests on liposarcoma models.

An immunosuppressant is a type of medication that suppresses or reduces the strength of the immune system.

Alnylam Unveils Encouraging Outcomes from Phase 2 KARDIA-2 Trial with Zilebesiran on Top of Usual Hypertension Medications in Subjects with Poorly Managed High Blood Pressure.

Drug stability testing is a critical part of pharmaceutical development that assesses the physical, chemical, and microbiological stability of a drug product under various storage conditions over time.

Recent insights reveal that supplementing standard statin treatment with semi-annual doses of Leqvio® (inclisiran) can markedly decrease bad cholesterol levels in individuals with atherosclerotic cardiovascular disease in practical healthcare situations.

Herbal medicine preparation refers to the process of transforming plant materials—such as leaves, flowers, seeds, roots, and bark—into forms that can be used for therapeutic purposes.

Ocugen Reports Encouraging Results and DSMB Assessment, Launches Participant Recruitment for Intermediate Dosage Trial of OCU410, a Genetic Treatment Option, in Early-Stage ArMaDa Research Targeting Geographic Atrophy.